Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers

Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar Unveiling

January 5, 2018 12:40 PM EST

Stifel analyst Alex Schwartz raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $15.00 (from $12.00) while maintaining a Hold rating after the company announced positive topline data from the Phase 1 trial with M281.

Schwartz commented, "The anti-FcRn antibody demonstrated a favorable safety profile... More